Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis
✍ Scribed by C.E.M. Griffiths; E.J.M. Van Leent; M. Gilbert; J. Traulsen
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 301 KB
- Volume
- 147
- Category
- Article
- ISSN
- 0007-0963
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
Therapeutic options to treat atopic dermatitis are limited. leukocytes from atopic patients have an abnormally high activity of cyclic adenosine monophosphate (amp)-phosphodiesterase (pde), which can be normalized in vitro by pde inhibitors. cipamfylline is a new potent and selective inhibitor of pde-4.
Objectives:
To compare the efficacy and safety of up to 14 days' topical treatment with cipamfylline (0.15%) cream with vehicle and with hydrocortisone 17-butyrate (0.1%) cream.
Patients and methods:
International, multicentre, prospective, randomized double-blind, left-right studies of cipamfylline vs. vehicle and cipamfylline vs. hydrocortisone 17-butyrate in adult patients with stable symmetrical atopic dermatitis on the arms.
Results:
Both cipamfylline and hydrocortisone 17-butyrate reduced the total severity score significantly (p < 0.001). the reduction with cipamfylline was significantly greater than that with vehicle (difference vehicle-cipamfylline 1.67 95% confidence interval (ci) 1.06, 2.28; p < 0.001) and was significantly less than with hydrocortisone 17-butyrate (difference hydrocortisone-cipamfylline -2.10 95% ci -2.93, -1.27; p < 0.001). investigator and patient assessments of the overall treatment response showed a similar picture.
Conclusions:
Cipamfylline cream is significantly more effective than vehicle, but significantly less effective than hydrocortisone 17-butyrate cream in the treatment of atopic dermatitis.